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Objective: To quantify the association between high-density lipoprotein (HDL) subfrac-
tions, efflux capacity, and inflammatory markers at baseline and the effect of supervised 
exercise on these HDL parameters in patients with peripheral artery disease (PAD).
Methods: The study to improve leg circulation (SILC) was a randomized trial of super-
vised treadmill exercise, leg resistance training, or control in individuals with PAD. In a 
post hoc cross-sectional analysis, we quantified the associations between baseline HDL 
subfraction concentrations (HDL2 and HDL3), HDL-C efflux capacity, and inflammatory 
markers [C-reactive protein (CRP) and interleukin-6 (IL-6)]. We then examined the effect 
of supervised exercise on changes in these lipoprotein parameters and inflammatory 
markers in 88 patients from SILC.
results: Baseline HDL-C efflux capacity was associated with baseline concentrations 
of HDL2 (β = 0.008, p = 0.0106), HDL3 (β = 0.013, p < 0.0001), and IL-6 (β = −0.019, 
p = 0.03). Baseline HDL3 concentration was inversely associated with IL-6 concentra-
tion (β = −0.99, p = 0.008). Compared to control, changes in HDL2, HDL3, normalized 
HDL-C efflux capacity, CRP, or IL-6 were not significantly different at 6 months following 
the structured exercise intervention.
Abbreviations: HDL2, high-density lipoprotein-2 cholesterol; HDL3, high-density lipoprotein-3 cholesterol.
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inTrODUcTiOn
Exercise has been observed to alter high-density lipoprotein 
(HDL) metrics associated with the risk of cardiovascular 
disease (CVD), including increased HDL subfractions (1) in 
individuals without known CVD and increased HDL-C efflux 
capacity in observational studies of athletes (2, 3). Patients 
with peripheral artery disease (PAD) are at high risk for CVD 
events, including limb threatening and acute systemic ischemic 
events. Exercise (4) and physical activity (5) may be associated 
with reductions in levels of inflammatory markers, including 
C-reactive protein (CRP) and interleukin-6 (IL-6), which 
could slow disease progression, functional decline, and reduce 
risks for cardiovascular outcomes in PAD patients (6–8). 
Additionally, inflammation may interfere with the protective 
functions of HDL (i.e., efflux capacity) (9–11). However, little 
is known about the association among HDL metrics associated 
with CVD risk, inflammation, and exercise in patients with 
PAD (12–14).
High-density lipoprotein structure (as measured by subfrac-
tion concentration) is associated with CVD risk (15, 16), and 
measurement of HDL function (as measured by HDL-C efflux 
capacity) has emerged as a robust marker of prevalent and 
incident CVD (17). The clinical significance and profile of HDL 
subfractions in patients with PAD are also not well understood 
with reports of both increased (18) and decreased (19) HDL3 
levels in the setting of reduced HDL2 and HDL-C. The HDL 
subfractions, HDL2 and HDL3, are particles with unique size 
and density that may have distinct cholesterol efflux capacities 
(20), exhibit unique efflux responses to drug therapy (21), and 
have differential associations with CVD events (22). Thus, 
structural changes in HDL particles may be paralleled by func-
tional changes with implications for CVD risk (23). A previous 
meta-analysis of exercise on HDL subfractions in adults without 
known CVD demonstrated that exercise is associated with 
increased HDL2 (1). However, the effect of supervised exercise 
on HDL subfraction concentration and HDL efflux capacity in 
patients with PAD has not been studied.
The study to improve leg circulation (SILC) was a 6-month 
randomized trial of supervised treadmill exercise, leg resistance 
training, or control in individuals with PAD with and without 
claudication that demonstrated improved physical function and 
quality of life in response to a supervised exercise intervention 
compared to control. First, in a post  hoc analysis of the SILC 
study, we quantified the associations among HDL efflux, HDL 
subfractions, and circulating inflammatory markers at baseline 
in a cross-sectional analysis. Second, we evaluated the effect 
of 24  weeks of supervised exercise on changes in HDL efflux, 
HDL subfractions, and circulating inflammatory markers using 
changes in 6-min walk as a measure of response to the exercise 
intervention.
MaTerials anD MeThODs
Design Overview
The SILC trial enrolled 156 patients with PAD with and without 
intermittent claudication between April 1, 2004, and August 8, 
2008. Participants were recruited from newspaper and radio 
advertisements (n  =  85), non-invasive vascular laboratories 
at Northwestern Memorial Hospital and other Chicago-area 
hospitals, and via community mailings and posters. The institu-
tional review boards of the participating hospitals and medical 
centers approved the protocol. Patients were randomly assigned 
to supervised treadmill exercise (n = 51), lower extremity resist-
ance training (n = 52), or a control (n = 53) group. Details of 
the design, patients, outcome definitions, and results have been 
published (24). Baseline information concerning demographics 
[age, sex, race, body mass index, ankle brachial index (ABI), and 
smoking], past medical history (leg symptoms, diabetes, angina, 
myocardial infarction, heart failure, and cancer), and statin and 
glitazone use were collected at the time of enrollment in SILC.
study interventions
The supervised treadmill exercise intervention consisted of 
treadmill exercise three times a week for 24 weeks, supervised by 
an exercise physiologist. The duration and intensity of treadmill 
exercise was over the course of 24 weeks and/or at near maximal 
leg symptoms (if present). Participants in the lower extrem-
ity resistance training group exercised three times a week for 
24 weeks with a certified trainer. They performed three sets of 
eight repetitions of knee extension, leg press, and leg curl exer-
cises. For each exercise, one repetition maximum was measured 
at baseline and every 4 weeks, and weights were increased until 
participants lifted 80% of their one repetition maximum. The 
control group received 11 nutritional information sessions over 
6 months. “Nutritional information sessions were not provided to 
the supervised exercise groups.”
leg symptoms
Leg symptoms were assessed at baseline and follow-up using the 
San Diego claudication questionnaire (25). Intermittent claudica-
tion was defined as exertional calf pain that does not begin at rest, 
causes the subject to stop walking, and resolves within 10 min of 
rest (26).
conclusion: HDL efflux and HDL3 were inversely associated with IL-6 in PAD patients. 
Structured exercise was not associated with changes in HDL subfractions, HDL-C efflux 
capacity, CRP, and IL-6 in PAD patients. Our preliminary findings support the theory that 
inflammation may adversely affect HDL structure and function; however, further studies 
are needed to evaluate these findings.
Keywords: exercise, peripheral artery disease, high-density lipoprotein, hDl efflux capacity, hDl subfractions
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six-Minute Walk
At baseline and follow-up, 6-min walk performance was assessed 
using standardized protocols (27). Participants walked up and 
down a 100-ft hallway for 6  min after instructions to cover as 
much distance as possible. The distance completed after 6 min 
was recorded.
ankle Brachial index
A handheld Doppler probe (Nicolet Vascular Pocket Dop II; 
Nicolet Biomedical Inc., Golden, CO, USA) was used to obtain 
systolic pressures in the right and left brachial, dorsalis pedis, 
and posterior tibial arteries. Each pressure was measured twice. 
The ABI was calculated by dividing the mean of the dorsalis pedis 
and posterior tibial pressures in each leg by the mean of the four 
brachial pressures (28). Average pressures in the arm with the 
highest pressure were used when the first brachial pressure was 
higher than the opposite brachial pressure in both measurement 
sets and the second brachial pressures differed by 10 mm Hg or 
higher in the first measurement set (29).
circulating inflammatory Markers
Interleukin-6 was measured using an ultrasensitive enzyme-
linked immunosorbent assay (R&D Systems, Minneapolis, MN, 
USA). Concentrations of high-sensitivity CRP were determined 
using an immunoturbidimetric assay on the Hitachi 911 analyzer 
(Roche Diagnostics, Indianapolis, IN, USA), using reagents and 
calibrators from Denka Seiken (Niigata, Japan).
Measurement of hDl-c efflux capacity
Two hundred microliters of stored serum (100 μl baseline and 
100 μl follow-up) from PAD patients randomized to supervised 
exercise training and control were assayed for HDL-C efflux 
capacity.
Cholesterol efflux measurements were performed using the 
J774 radiolabeled cholesterol assay, which has been extensively 
used in studies of cholesterol efflux to human serum (30). J774 
cells (ATCC, Rockville, MD, USA), derived from a murine 
macrophage cell line, are plated and radiolabeled with 2 μCi 
of 3H-cholesterol per milliliter. ATP-binding cassette A1 
(ABCA1) is a transmembrane protein involved in reverse 
cholesterol transport (RCT) by functioning as a cholesterol 
efflux pump. ABCA1 is upregulated by means of an 18-h 
incubation with 0.3  mM 8-(4-chlorophenylthio)-cyclic AMP. 
Subsequently, efflux mediums containing 2.8% apolipoprotein 
B (apo-B)-depleted serum were added for 4 h. Apo-B-depleted 
serum was created by mixing 40 parts 20% PEG 6000 (QIAGEN 
Science, Germantown, MD, USA) with 100 parts serum with 
gentle mixing, and then incubated at room temperature for 
20 min. Apo-B-depleted serum was then obtained by recovery 
of supernatant following centrifugation (10,000 rpm, 30 min, 
4°C). All steps were performed in the presence of the acyl-
coenzyme A:cholesterol acyltransferase inhibitor CP113,818 
(2  μg/ml). This assay measures efflux mediated by several 
macrophage-specific RCT pathways, including the ABCA1- and 
ATP-binding cassette G1- (ABCG1) mediated transport, scav-
enger receptor B1-mediated transport, and aqueous diffusion 
(30, 31). Stimulation of J774 cells with cAMP upregulates 
ABCA1-mediated efflux. Thus in the conditions used here, total 
release of cholesterol occurred mainly by ABCA1 and passive 
diffusion.
Liquid scintillation counting was used to quantify the 
efflux of radioactive cholesterol from the cells. The quantity 
of radioactive cholesterol incorporated into cellular lipids 
was calculated by means of isopropanol extraction of control 
wells not exposed to patient serum. After serial washing with 
PBS, cell lipids were extracted from control culture dishes with 
isopropanol for 1 h, then evaporated to dryness under nitrogen 
gas, and were then reconstituted in chloroform. All assays were 
performed in triplicate. Percent efflux was calculated by the 
following formula:
 
[(microcuries of  3H - cholesterol in mediums containing 2.8% 
apolipoprotein B - depleted serum microcuries of  3H -
choles
−
terol in serum - free mediums microcuries of  3H -
cholestero
) /
l in cells extracted before the efflux step] .×100  
Values were normalized by dividing the efflux capacity of 
individual patients by the efflux capacity of a serum pool run 
with each assay.
lipoprotein and subfraction  
Measurement
The vertical auto profile (VAP) test was used to obtain a com-
prehensive measurement of the lipoprotein cholesterol profile. 
One hundred forty-two microliters of stored plasma (71  μl 
at baseline and 71  μl post-exercise) were analyzed from PAD 
patients randomized to supervised treadmill training (n = 33), 
strength training (n = 29), and age- and gender-matched controls 
(n =  26). The VAP test is based on a well-established method 
of ultracentrifugation for lipoprotein subfraction determina-
tion (32). VAP provides cholesterol concentrations of various 
lipoproteins subclasses, including the HDL subfractions HDL2 
and HDL3.
statistical analysis
Baseline characteristics were summarized as means and SDs, 
frequencies, and percentages, as appropriate. Chi-squared tests 
and one-way analyses of variance were used to compare baseline 
characteristics of participants across the three groups. Two sam-
ple, two-sided t-tests were used to compare changes in outcomes 
between 6-month follow-up and baseline between each exercise 
group and the control group, respectively, without adjustments 
for multiple comparisons. The Shapiro–Wilk test was used to 
assess for normality of the data.
Relationships between continuous variables of interest were 
assessed using Pearson correlation coefficients (denoted as r) and 
multivariable adjusted linear regression models adjusted for age, 
race, gender, HDL subfractions, inflammatory markers, smoking 
status, statin, and glitazone.
Two sample, two-sided t-tests were used to compare changes 
in outcomes between baseline and 6-month follow-up among the 
TaBle 1 | Baseline characteristics of peripheral artery disease according 
to study group assignment.
Baseline measures Treadmill 
(N = 33)
strength 
(N = 29)
control 
(N = 26)
p 
Value
Age (years), mean (SD) 71.45 (8.58) 73.48 (8.58) 67.62 (11.68) 0.08
Ankle brachial index, 
mean (SD)
0.60 (0.18) 0.60 (0.14) 0.59 (0.18) 0.9
Male sex, n (%) 14 (42.42) 13 (44.83) 14 (53.85) 0.7
Black race, n (%) 16 (48.48) 7 (24.14) 13 (50.00) 0.08
Body mass index (kg/m2), 
mean (SD)
29.85 (5.84) 29.44 (7.08) 30.51 (8.46) 0.9
6-min walk distance (m), 
mean (SD)
337.26 
(86.59)
306.03 
(95.77)
325.42 
(99.26)
0.4
Diabetes, n (%) 11 (33.33) 12 (41.38) 12 (46.15) 0.6
Current smoker, n (%) 8 (24.24) 5 (17.24) 10 (38.46) 0.2
Angina, n (%) 3 (9.09) 5 (18.52) 2 (7.69) 0.4
Myocardial infarction, 
n (%)
7 (21.88) 7 (25.00) 3 (11.54) 0.4
Heart failure, n (%) 2 (6.25) 3 (10.34) 2 (7.69) 0.8
Cancer, n (%) 6 (18.18) 3 (10.34) 2 (7.69) 0.4
HDL2-C (mg/dl) 13.79 (8.78) 11.76 (5.31) 12.65 (7.53) 0.6
HDL3-C (mg/dl) 38.09 (10.06) 33.83 (6.53) 34.65 (9.79) 0.1
HDL-C (mg/dl) 51.88 (17.99) 45.59 (10.70) 47.31 (16.62) 0.3
Normalized efflux 1.15 (0.20) 1.15 (0.20) 1.11 (0.25) 0.8
Intermittent claudication, 
n (%)
9 (27.27) 3 (10.34) 4 (15.38) 0.2
On statins, n (%) 21 (63.64) 17 (58.62) 13 (50.00) 0.6
On glitazones, n (%) 4 (12.12) 2 (6.90) 1 (3.85) 0.6
HDL-C, high-density lipoprotein cholesterol; HDL2, high-density lipoprotein-2 
cholesterol; HDL3, high-density lipoprotein-3 cholesterol.
FigUre 1 | Beta coefficients of linear regression modeling examining 
the association of baseline cholesterol efflux stratified according to 
baseline quartiles of interleukin-6 (il-6) in all study participants.
4
Albaghdadi et al. Exercise, Efflux, and Subfractions in PAD
Frontiers in Cardiovascular Medicine | www.frontiersin.org March 2017 | Volume 4 | Article 9
treadmill, strength training, and control groups without adjust-
ment for baseline data.
The p value considered statistically significant was p ≤ 0.05. 
All analyses were performed using the SAS statistical software 
(version 9.4, SAS Institute Inc., Cary, NC, USA).
sample size Power calculation
Since we used macrophage-to-plasma efflux capacity as in the 
study by Olchawa et al., sample size estimation was performed 
using the effect size and SDs of their study. To detect a difference 
of 2.6% (18.8 vs. 16.2%), we estimated that we would need 22 
subjects per group to have an 80% chance of having a statistically 
significant result at p = 0.05.
resUlTs
study Participants
One hundred fifty-six PAD patients were enrolled in the SILC 
study, 68 were excluded because of lack of availability of baseline 
or follow-up serum sample. Patients were randomly assigned to 
supervised treadmill exercise (n = 51), lower extremity resistance 
training (n = 52), or a control (n = 53) group. Among those not 
included, there was a higher prevalence of heart failure (12 vs. 
7%, p = 0.02) and cancer (17 vs. 11%, p = 0.04) compared to the 
subjects included in the current sub-study. The characteristics of 
SILC trial participants are shown in Table 1. The mean age of the 
participants was 70.85 ± 1.72 years. A total of 53.5% of patients 
were women and 46.5% were black. There were no significant 
differences in baseline demographics, CV risk factors or disease, 
severity of PAD, 6-min walk, or HDL-related parameters in any 
of the study groups. There were also no significant differences in 
baseline characteristics from study onset to completion following 
the study interventions.
association of Baseline hDl subfractions, 
inflammatory Markers, comorbidities, and 
Medications with Baseline cholesterol 
efflux capacity
In all study patients, HDL-C (β =  0.006, p =  0.0001), HLD2 
(β = 0.008, p = 0.0105), HDL3 (β = 0.011, p < 0.0001), and IL-6 
(β = −0.019, p = 0.0294) but not CRP was associated with baseline 
HDL-C efflux capacity. However, after adjustment for age, race, 
gender, current smoking status, IL-6, statin, and glitazone use, 
only HDL3 (β = 0.0147, p = 0.0014) was associated with baseline 
cholesterol efflux capacity. Including diabetes, heart failure, coro-
nary artery disease, and cancer into the adjusted model did not 
change the magnitude or statistical significance of the association 
between baseline HDL3 with baseline HDL efflux.
Additionally, there was no significant difference in base-
line HDL-C efflux capacity in patients receiving statins vs. 
not receiving statins (mean efflux =  1.18 vs. 1.10, p =  0.61, 
respectively), or in patients receiving glitazones vs. those not 
receiving glitazones (mean efflux =  1.13 vs. 1.18, p =  0.21, 
respectively).
association of Baseline hDl subfractions 
and inflammatory Markers
In an unadjusted analysis, we observed an inverse association 
between baseline IL-6 levels and baseline HDL3 concentration 
(β = −0.99, p = 0.008). This association was minimally altered 
AB
C
FigUre 2 | continued
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(β = −0.94, p =  0.01) after adjustment for age, race, gender, 
current smoking status, comorbidities, statin, and glitazone use. 
In addition, among patients with the highest quartile of IL-6, 
a trend toward an inverse association was observed between 
baseline IL-6 and baseline efflux capacity (β = −0.1167, p = 0.08) 
(Figure 1).
DE
FigUre 2 | changes in (a) high-density lipoprotein (hDl) subfractions, (B) cholesterol efflux capacity, and (c) inflammatory markers among 
peripheral artery disease in study to improve leg circulation patients according to group assignment. All values are average ± SE. (a) p = 0.38 for 
strength, treadmill, and diet control groups compared to baseline. For differences compared to control at 6-month follow-up: strength (p = 0.7) and treadmill 
(p = 0.3). (B) p = 0.9 for strength, treadmill, and diet control compared to baseline. For differences compared to control at 6-month follow-up: p = 0.7 for strength 
and p = 0.8 for treadmill. (c) p = 0.9 for strength, treadmill, and diet control compared to baseline. For differences compared to control at 6-month follow-up, 
p = 0.7 for strength and p = 0.7 for treadmill. (D) p = 0.99 for strength, treadmill, and diet control compared to baseline. For differences compared to control at 
6-month follow-up, p = 0.9 for strength and p = 0.98 for treadmill. (e) p = 0.8 for strength, treadmill, and diet control compared to baseline. For differences 
compared to control at 6-month follow-up, p = 0.7 for strength and p = 0.8 for treadmill.
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association of exercise with changes  
in hDl subfractions, cholesterol  
efflux capacity, and inflammatory  
Markers
There were no significant changes in HDL2 and HDL3 compared 
to baseline in the strength trained group [(−0.17  mg/dl, 95% 
CI: −1.88 to −1.54) and (1.24  mg/dl, 95% CI: −0.85 to 3.33), 
respectively] and treadmill group [(1.42  mg/dl, 95% CI: −0.18 
to 3.03) and (1.42 mg/dl, 95% CI: −0.54 to 3.39), respectively] 
(Figures 2A,B). Additionally, there was no significant difference 
in HDL2 and HDL3 in the strength and treadmill groups at 
6 months follow compared to control.
No significant changes were observed in normalized cho-
lesterol efflux capacity compared to baseline and control at 
6-month follow-up in the strength trained group [(−0.02, 95% 
CI: −0.1 to 0.07) and (0.03, 95% CI: −0.1 to 0.15; p =  0.7), 
respectively] and treadmill group [(−0.02, 95% CI: 0.1–0.06) and 
(0.02, 95% CI: −0.1 to 0.14; p = 0.7), respectively] (Figure 2C). 
Additionally, no changes were observed in the mean levels 
of IL-6 or CRP from baseline to follow-up (Figures  2D,E). 
Lastly, there was no association between changes in HDL-C 
efflux capacity, HDL2, HDL3, or inflammatory markers 
(Table  2) among the treadmill, resistance trained, or control 
groups.
The relationship between changes in 6-min walk distance and 
changes in cholesterol efflux capacity, HDL2, HDL3, CRP, and 
IL-6 is shown for individual study participants in Figure 3. As 
depicted in Figure 3, there is no evidence of a linear relationship 
between changes in functional capacity as a result of the exer-
cise interventions, HDL-related parameters, and inflammatory 
mediators.
TaBle 2 | association of changes in high-density lipoprotein (hDl) efflux, 
hDl subfractions, and circulating inflammatory markers with changes in 
6-min walk.
change in Pearson correlation coefficients
change in 6-min walk
Treadmill strength training control
Efflux 0.0351  
(p value = 0.8464, 
n = 33)
0.0729  
(p value = 0.7070, 
n = 29)
0.0591  
(p value = 0.7743, 
n = 26)
HDL2-C 0.1398  
(p value = 0.4377, 
n = 33)
−0.3508  
(p value = 0.0621, 
n = 29)
0.1049  
(p value = 0.6099, 
n = 26)
HDL3-C −0.0328  
(p value = 0.8562, 
n = 33)
−0.2323  
(p value = 0.2253, 
n = 29)
−0.0006  
(p value = 0.9976, 
n = 26)
CRP −0.0754  
(p value = 0.6920, 
n = 30)
−0.0934  
(p value = 0.6299, 
n = 29)
0.1432  
(p value = 0.4947, 
n = 25)
IL-6 −0.3256  
(p value = 0.0791, 
n = 30)
−0.2054  
(p value = 0.2851, 
n = 29)
−0.1098  
(p value = 0.6015, 
n = 25)
Efflux, HDL-C efflux capacity; HDL2, high-density lipoprotein-2 cholesterol; HDL3, 
high-density lipoprotein-3 cholesterol; CRP, C-reactive protein, IL-6, interleukin-6.
FigUre 3 | continued
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DiscUssiOn
Our results show that supervised strength and treadmill exercise 
training are not associated with changes in HDL subfractions, 
cholesterol efflux capacity, or inflammatory markers in patients 
with PAD. We observed an association between baseline HDL 
subfraction concentrations and HDL efflux, an inverse association 
between baseline IL-6 and HDL efflux, and an inverse association 
between baseline IL-6 and HDL3 concentration.
The SILC study demonstrated that exercise is associated with 
beneficial effects in patients with PAD, including improving 
walking distance, endothelial function, and quality of life (24). 
However, the mechanisms underlying the beneficial effects of 
exercise are not well understood in PAD. We studied an assay 
of HDL-mediated RCT thought to reflect the most relevant 
pathways involved in atheroprotection (33), and measured 
HDL subfractions that have been implicated in RCT (34, 35) 
to explore the biologic mechanisms underlying the favorable 
effects of exercise. Our results suggest that the beneficial effects 
of exercise in patients with PAD do not include favorable 
changes in HDL structure or function as measured by HDL 
subfraction or efflux, respectively. To our knowledge, this study 
represents the first investigation of the effect of structured 
exercise interventions on these HDL-related metrics in patients 
with PAD.
Supervised exercise did not alter HDL-C, structure, or function 
as measured in our post hoc analysis of the SILC cohort. A possible 
explanation for these findings is that a sufficient “exercise dose” 
may be necessary to increase HDL-C concentration in individu-
als without known CVD (1, 36, 37), and PAD patients may not 
exercise at a sufficient intensity to achieve such beneficial changes. 
Importantly, it is not known if such an exercise threshold exists to 
favorably remodel HDL subfractions and/or improve HDL efflux 
in patients with PAD, or even if HDL efflux is modified by exercise 
in patients with PAD. Koba et al. recently observed an increase 
in HDL efflux capacity compared to baseline following 6 months 
of cardiac rehabilitation and intensive lifestyle modification 
counseling in 57 patients with a recent acute coronary syndrome 
compared to baseline levels but no significant increase compared 
to 11 control patients who did not undergo these interventions 
(38). In a bivariate analysis, they observed that increased HDL 
efflux was associated with increased HDL-C, apolipoprotein A1, 
and high-intensity statin use. Interestingly, only patients who 
achieved a high level of exercise tolerance (defined as a peak 
VO2 ≥  19  ml/min/kg) and “complete risk factor control” were 
FigUre 3 | continued
FigUre 3 | scatter plots of the relationship between changes in 6-min 
walk and changes in (a) cholesterol efflux capacity, (B) hDl2, (c) 
hDl3, (D) c-reactive protein (crP), and (e) interleukin-6 (il-6).
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observed to have a significant increase in HDL efflux capacity 
suggesting an exercise dose–response relationship may exist 
between exercise and efflux. In contrast to the PAD population 
examined in the current study, the study population of Koba et al. 
was significantly younger with fewer comorbidities and received 
a more intensive study intervention that included 6  months 
of supervised exercise and lifestyle modification counseling. 
Importantly, HDL-C may not increase with exercise in patients 
with baseline low levels of HDL-C (39) as is often observed in 
patients with PAD (40). Furthermore, increased skeletal muscle 
blood during physical activity and subsequent activation of lipo-
protein lipase may be an important mechanism for increasing the 
concentration of HDL subfractions following exercise, a process 
that may be significantly diminished in patients with PAD and 
flow-limiting atherosclerotic lesions in the arterial circulation of 
their lower extremities (41).
Another possible explanation for our findings may be that 
patients with severe established atherosclerosis, such as those 
with PAD, have dysfunctional HDL that is not amenable to 
improvement via structured exercise or pharmacologic interven-
tion (9, 10, 42). Contrary to other studies of cholesterol efflux 
capacity in patients with CVD, we did not observe a positive 
association between HDL efflux and treatment with statin or 
glitazone medications (30, 38, 43). We did observe, however, a 
univariate association between baseline IL-6 levels and HDL-C 
efflux capacity (which was lost after adjustment), and a multi-
variate association between HDL3 and efflux. PAD patients have 
elevated levels of IL-6 (44), which may modulate cholesterol 
efflux to HDL (45–47). It remains unclear if examination of a 
larger number of inflammatory mediators would have provided 
additional evidence of an association between inflammation and 
the HDL-related metrics examined in our study. We also observed 
that HDL-C efflux in the PAD subjects was elevated compared to 
the referent pool (i.e., normalized value above 1), and that HDL 
efflux was refractory to exercise intervention. A normalized efflux 
value greater than 1 suggests that HDL-C efflux capacity may have 
been near maximal and therefore not amenable to augmentation 
in this older cohort with advanced PAD (or that normalization of 
efflux was performed using an unhealthy referent pool).
Importantly, compared to other studies of HDL efflux and 
CVD, our study cohort was significantly older with more 
advanced atherosclerotic burden, and therefore exercise and 
9Albaghdadi et al. Exercise, Efflux, and Subfractions in PAD
Frontiers in Cardiovascular Medicine | www.frontiersin.org March 2017 | Volume 4 | Article 9
pharmacologic interventions may be less effective in modifying 
efflux capacity than they might be in younger individuals.
Our study has several limitations. First, the analyses are 
post hoc and should be considered exploratory. Second, the small 
sample size may have contributed to lack of statistical power 
to detect an effect of exercise on efflux and HDL subfractions; 
however, our a priori power analysis suggested this was not so. 
Third, we examined many comparisons, and our analyses did not 
adjust for multiple comparisons. Our findings regarding baseline 
HDL subfraction, IL-6, and HDL efflux may be due to chance, 
and adjustment for multiple comparisons was not possible since 
most results of this study were not significant. Additionally, a 
number of factors may have affected the accuracy of this sample 
size estimate, including that the impact of chronic exercise has 
not been evaluated in patients with PAD and may be increased 
or decreased compared to healthy controls, which would either 
decrease or increase, respectively, the sample size requirements. 
In addition, Olchawa et al. study did not normalize efflux values 
relative to a control serum pool run with each assay. Using this 
normalization technique may theoretically increase the SDs and 
thus sample size.
cOnclUsiOn
In this post  hoc analysis of PAD patients from the SILC study, 
metrics of HDL structure (HDL3) and function (efflux) were 
inversely associated with a marker of systemic inflammation 
(IL-6) at baseline; however, the association of IL-6 with HDL 
efflux was lost after adjustment for comorbidities and HDL3. 
Supervised exercise did not alter the HDL subfraction profile, 
improve HDL-C efflux capacity, or modulate levels of CRP and 
IL-6 in PAD patients from SILC. Future studies of the effect of 
structured exercise on these HDL-related metrics may be war-
ranted in patients with PAD and elevated inflammatory markers.
eThics sTaTeMenT
Northwestern University Feinberg School of Medicine 
Institutional Review Board approved this study. Patient consent 
was obtained at the time of the original SILC study for study 
sample analysis.
aUThOr cOnTriBUTiOns
Conceived study, designed experiments, and composed manu-
script (MA, JW, and RM); financial support (JW and RM); edited 
manuscript (MA, ZW, YG, RM, and JW); and performed experi-
ments and analyzed data (MA, ZW, and YG).
FUnDing
The authors would like to thank Dr. Neil Stone, MD for his gra-
cious intellectual and financial support of this work. The authors 
would also like to thank to Atherotech® Diagnostics Lab for their 
assistance of lipoprotein subfraction analyses.
reFerences
1. Kelley GA, Kelley KS. Aerobic exercise and HDL2-C: a meta-analysis of 
randomized controlled trials. Atherosclerosis (2006) 184:207–15. doi:10.1016/ 
j.atherosclerosis.2005.04.005 
2. Olchawa B, Kingwell BA, Hoang A, Schneider L, Miyazaki O, Nestel P, et al. 
Physical fitness and reverse cholesterol transport. Arterioscler Thromb Vasc 
Biol (2004) 24:1087–91. doi:10.1161/01.ATV.0000128124.72935.0f 
3. Brites F, Verona J, De Geitere C, Fruchart JC, Castro G, Wikinski R. Enhanced 
cholesterol efflux promotion in well-trained soccer players. Metabolism (2004) 
53:1262–7. doi:10.1016/j.metabol.2004.05.002 
4. Tisi PV, Shearman CP. Biochemical and inflammatory changes in the 
exercising claudicant. Vasc Med (1998) 3:189–98. doi:10.1177/1358836X 
9800300303 
5. Craft LL, Guralnik JM, Ferrucci L, Liu K, Tian L, Criqui MH, et al. Physical 
activity during daily life and circulating biomarker levels in patients with 
peripheral arterial disease. Am J Cardiol (2008) 102:1263–8. doi:10.1016/ 
j.amjcard.2008.06.051 
6. Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Pearce WH, et  al. 
Biomarkers of inflammation and thrombosis as predictors of near-term 
mortality in patients with peripheral arterial disease: a cohort study. Ann 
Intern Med (2008) 148:85–93. doi:10.7326/0003-4819-148-2-200801150- 
00003 
7. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. 
C-reactive protein, interleukin-6, and soluble adhesion molecules as pre-
dictors of progressive peripheral atherosclerosis in the general population: 
Edinburgh Artery study. Circulation (2005) 112:976–83. doi:10.1161/
CIRCULATIONAHA.104.513085 
8. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of use-
fulness of inflammatory markers in patients with versus without peripheral 
arterial disease in predicting adverse cardiovascular outcomes (myocardial 
infarction, stroke, and death). Am J Cardiol (2005) 96:1374–8. doi:10.1016/ 
j.amjcard.2005.07.041 
9. de la Llera-Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, 
Nguyen V, et  al. Inflammation modulates human HDL composition 
and function in  vivo. Atherosclerosis (2012) 222:390–4. doi:10.1016/ 
j.atherosclerosis.2012.02.032 
10. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, 
et  al. Abnormal lipoprotein particles and cholesterol efflux capacity in 
patients with psoriasis. Atherosclerosis (2012) 224:218–21. doi:10.1016/ 
j.atherosclerosis.2012.06.068 
11. Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, et al. 
The association between reduction in inflammation and changes in lipopro-
tein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am 
Heart Assoc (2015) 4:e001588. doi:10.1161/JAHA.114.001588 
12. Mowat BF, Skinner ER, Wilson HM, Leng GC, Fowkes FG, Horrobin D. 
Alterations in plasma lipids, lipoproteins and high density lipoprotein 
subfractions in peripheral arterial disease. Atherosclerosis (1997) 131:161–6. 
doi:10.1016/S0021-9150(97)06097-8 
13. Rein P, Saely CH, Silbernagel G, Vonbank A, Mathies R, Drexel H, et  al. 
Systemic inflammation is higher in peripheral artery disease than in stable 
coronary artery disease. Atherosclerosis (2015) 239:299–303. doi:10.1016/ 
j.atherosclerosis.2015.01.021 
14. Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in 
peripheral artery disease. Circulation (2010) 122:1862–75. doi:10.1161/
CIRCULATIONAHA.109.918417 
15. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, 
HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. 
A prospective population study in eastern Finnish men. Circulation (1991) 
84:129–39. doi:10.1161/01.CIR.84.1.129 
16. Sich D, Saidi Y, Giral P, Lagrost L, Egloff M, Auer C, et  al. 
Hyperalphalipoproteinemia: characterization of a cardioprotective 
10
Albaghdadi et al. Exercise, Efflux, and Subfractions in PAD
Frontiers in Cardiovascular Medicine | www.frontiersin.org March 2017 | Volume 4 | Article 9
profile associating increased high-density lipoprotein 2 levels and decreased 
hepatic lipase activity. Metabolism (1998) 47:965–73. doi:10.1016/S0026- 
0495(98)90352-3 
17. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL 
cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 
(2014) 371(25):2383–93. doi:10.1056/NEJMoa1409065 
18. Kasko M, Gaspar L, Dukat A, Gavornik P, Oravec S. High-density lipoprotein 
profile in newly-diagnosed lower extremity artery disease in Slovak popula-
tion without diabetes mellitus. Neuro Endocrinol Lett (2014) 35:531–5. 
19. Kalofoutis A, Papapanagiotou A, Tzivras M. Clinical significance of plasma 
HDL subfractions (HDL2, HDL3) in patients with peripheral arterial disease 
(PAD) in the Greek population. Clin Biochem (1999) 32:149–52. doi:10.1016/
S0009-9120(98)00099-X 
20. Julia Z, Duchene E, Fournier N, Bellanger N, Chapman MJ, Le Goff W, et al. 
Postprandial lipemia enhances the capacity of large HDL2 particles to mediate 
free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipid-
emia. J Lipid Res (2010) 51:3350–8. doi:10.1194/jlr.P009746 
21. Catalano G, Julia Z, Frisdal E, Vedie B, Fournier N, Le Goff W, et al. Torcetrapib 
differentially modulates the biological activities of HDL2 and HDL3 particles 
in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 
(2009) 29:268–75. doi:10.1161/ATVBAHA.108.179416 
22. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopu-
lations and their relevance to cardiovascular disease. Trends Mol Med (2011) 
17:594–603. doi:10.1016/j.molmed.2011.05.013 
23. Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, 
et al. Translation of high-density lipoprotein function into clinical practice: 
current prospects and future challenges. Circulation (2013) 128:1256–67. 
doi:10.1161/CIRCULATIONAHA.113.000962
24. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et  al. 
Treadmill exercise and resistance training in patients with peripheral arterial 
disease with and without intermittent claudication: a randomized controlled 
trial. JAMA (2009) 301:165–74. doi:10.1001/jama.2008.962 
25. Criqui MH, Denenberg JO, Bird CE, Fronek A, Klauber MR, Langer RD. 
The correlation between symptoms and non-invasive test results in patients 
referred for peripheral arterial disease testing. Vasc Med (1996) 1:65–71. 
doi:10.1177/1358863X9600100112 
26. Rucker-Whitaker C, Greenland P, Liu K, Chan C, Guralnik JM, Criqui MH, 
et al. Peripheral arterial disease in African Americans: clinical characteristics, 
leg symptoms, and lower extremity functioning. J Am Geriatr Soc (2004) 
52:922–30. doi:10.1111/j.1532-5415.2004.52259.x 
27. Montgomery PS, Gardner AW. The clinical utility of a six-minute walk test 
in peripheral arterial occlusive disease patients. J Am Geriatr Soc (1998) 
46:706–11. doi:10.1111/j.1532-5415.1998.tb03804.x 
28. McDermott MM, Criqui MH, Liu K, Guralnik JM, Greenland P, Martin GJ, 
et al. Lower ankle/brachial index, as calculated by averaging the dorsalis pedis 
and posterior tibial arterial pressures, and association with leg functioning 
in peripheral arterial disease. J Vasc Surg (2000) 32:1164–71. doi:10.1067/
mva.2000.108640 
29. Shadman R, Criqui MH, Bundens WP, Fronek A, Denenberg JO, Gamst AC, 
et al. Subclavian artery stenosis: prevalence, risk factors, and association with 
cardiovascular diseases. J Am Coll Cardiol (2004) 44:618–23. doi:10.1016/ 
j.jacc.2004.04.044 
30. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, 
et al. Cholesterol efflux capacity, high-density lipoprotein function, and ath-
erosclerosis. N Engl J Med (2011) 364:127–35. doi:10.1056/NEJMoa1001689 
31. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein 
J, et  al. Cholesterol efflux and atheroprotection: advancing the concept of 
reverse cholesterol transport. Circulation (2012) 125:1905–19. doi:10.1161/
CIRCULATIONAHA.111.066589 
32. Kulkarni KR, Marcovina SM, Krauss RM, Garber DW, Glasscock AM, Segrest 
JP. Quantification of HDL2 and HDL3 cholesterol by the vertical auto pro-
file-II (VAP-II) methodology. J Lipid Res (1997) 38:2353–64. 
33. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the 
regression of atherosclerosis? Circulation (2006) 113:2548–55. doi:10.1161/
CIRCULATIONAHA.104.475715 
34. Linsel-Nitschke P, Jansen H, Aherrarhou Z, Belz S, Mayer B, Lieb W, 
et  al. Macrophage cholesterol efflux correlates with lipoprotein subclass 
distribution and risk of obstructive coronary artery disease in patients 
undergoing coronary angiography. Lipids Health Dis (2009) 8:14. 
doi:10.1186/1476-511X-8-14 
35. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved 
in the athero-protective effect of high density lipoproteins. J Intern Med (2008) 
263:256–73. doi:10.1111/j.1365-2796.2007.01898.x 
36. King AC, Haskell WL, Young DR, Oka RK, Stefanick ML. Long-term effects 
of varying intensities and formats of physical activity on participation rates, 
fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 
(1995) 91:2596–604. doi:10.1161/01.CIR.91.10.2596 
37. Kokkinos PF, Fernhall B. Physical activity and high density lipoprotein 
cholesterol levels: what is the relationship? Sports Med (1999) 28:307–14. 
doi:10.2165/00007256-199928050-00002 
38. Koba S, Ayaori M, Uto-Kondo H, Furuyama F, Yokota Y, Tsunoda F, et  al. 
Beneficial effects of exercise-based cardiac rehabilitation on high-density lipo-
protein-mediated cholesterol efflux capacity in patients with acute coronary 
syndrome. J Atheroscler Thromb (2016) 23:865–77. doi:10.5551/jat.34454 
39. Couillard C, Despres JP, Lamarche B, Bergeron J, Gagnon J, Leon AS, et al. 
Effects of endurance exercise training on plasma HDL cholesterol levels 
depend on levels of triglycerides: evidence from men of the health, risk factors, 
exercise training and genetics (HERITAGE) family study. Arterioscler Thromb 
Vasc Biol (2001) 21:1226–32. doi:10.1161/hq0701.092137 
40. Bradby GV, Valente AJ, Walton KW. Serum high-density lipoproteins 
in peripheral vascular disease. Lancet (1978) 2:1271–4. doi:10.1016/
S0140-6736(78)92038-X 
41. Ruys T, Sturgess I, Shaikh M, Watts GF, Nordestgaard BG, Lewis B. Effects 
of exercise and fat ingestion on high density lipoprotein production by 
peripheral tissues. Lancet (1989) 2:1119–22. doi:10.1016/S0140-6736(89) 
91488-8 
42. Roe A, Hillman J, Butts S, Smith M, Rader D, Playford M, et al. Decreased 
cholesterol efflux capacity and atherogenic lipid profile in young women 
with PCOS. J Clin Endocrinol Metab (2014) 99:E841–7. doi:10.1210/ 
jc.2013-3918 
43. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, et al. Dose-
dependent action of atorvastatin in type IIB hyperlipidemia: preferential and 
progressive reduction of atherogenic apoB-containing lipoprotein subclasses 
(VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol 
efflux. Atherosclerosis (2002) 163:287–96. doi:10.1016/S0021-9150(02) 
00037-0 
44. McDermott MM, Guralnik JM, Corsi A, Albay M, Macchi C, Bandinelli S, 
et  al. Patterns of inflammation associated with peripheral arterial disease: 
the InCHIANTI study. Am Heart J (2005) 150:276–81. doi:10.1016/ 
j.ahj.2004.09.032 
45. Salminen A, Pussinen PJ, Payne JB, Stoner JA, Jauhiainen M, Golub LM, 
et  al. Subantimicrobial-dose doxycycline treatment increases serum cho-
lesterol efflux capacity from macrophages. Inflamm Res (2013) 62:711–20. 
doi:10.1007/s00011-013-0626-z 
46. Robert J, Lehner M, Frank S, Perisa D, von Eckardstein A, Rohrer L. Interleukin 
6 stimulates endothelial binding and transport of high-density lipoprotein 
through induction of endothelial lipase. Arterioscler Thromb Vasc Biol (2013) 
33:2699–706. doi:10.1161/ATVBAHA.113.301363 
47. Frisdal E, Lesnik P, Olivier M, Robillard P, Chapman MJ, Huby T, et  al. 
Interleukin-6 protects human macrophages from cellular cholesterol accu-
mulation and attenuates the proinflammatory response. J Biol Chem (2011) 
286:30926–36. doi:10.1074/jbc.M111.264325 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Albaghdadi, Wang, Gao, Mutharasan and Wilkins. This is 
an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
